Biocon has received the green light from the Food and Drug Administration, for its complex formulation liraglutide injection, 18 mg/3 ml (6 mg/ml) single-patient-use prefilled pen ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication. It helps with sustained weight loss for adults with obesity, adults with overweight who are experiencing weight-related health issues ...

The medication is indicated as an adjunct to a reduced–calorie diet and increased physical activity for chronic weight management.

Teva Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration for the first generic GLP-1 medication for weight loss, the Parsippany-based company announced Aug. 28. The ...

In a new study published in the JAMA Network Open medical journal, Novo Nordisk A/S’s (NYSE:NVO) Saxenda (liraglutide), an earlier-generation weight loss drug, reveals significant declines in bone ...

The Food and Drug Administration signed off on the first-ever weight-loss generic on Thursday, a knockoff of Novo Nordisk'sNVO Saxenda from Teva PharmaceuticalTEVA. Saxenda, the branded name for ...

(RTTNews) - Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), Thursday said that the U.S. Food and Drug Administration (FDA) has approved a generic version of ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

Obesity and weight-related health conditions have steadily risen over the past few decades, making weight management a ...

Generic Saxenda ® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s ...